Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reference Materials

This article was originally published in SRA

Executive Summary

Argentina establishes material for evaluation of gramicidin

Argentina establishes material for evaluation of gramicidin

The Argentinian National Administration of Medicines, Foods and Medical Technology, Anmat, has issued a regulation establishing the primary reference substance for microbiological evaluations of gramicidin1. Gramicidin is an antimicrobial cyclic polypeptide produced by the growth of bacillus brevis dubos that acts against a wide range of bacteria. It is used alone or in combination with other topical antibiotics or antiseptics in ointments, solutions or sprays for the treatment of infected burns, ulcers and wounds.

The reference material is packed in vials containing approximately 200mg of gramicidin with a given potency of 1118 IU/mg, expressed in dried substance, as determined in comparison with gramicidin CRS, Lot 1, established by the European Pharmacopoeia Commission. The standards will be stored at the National Institute of Medicines (INAME) and will be supplied to applicants subject to payment of the corresponding fee. The vials will be supplied with a summary of the complementary technical information.

MIGUEL JC NAPOLITANO

References

1. Anmat Disposici�n 6975/2006, 23 November 2006, Boletín Oficial de la República Argentina, No 31.072, 12 January 2007

Latest Headlines
See All
UsernamePublicRestriction

Register

PS112234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel